검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | chimeric antigen receptor T cell treatment (chimeric antigen receptor T cell treatment) Yake Biotechnology Ltd.·FRα ORR 80.3% |
|---|---|
Overview Program | chimeric antigen receptor T cell treatment |
Overview Company | Yake Biotechnology Ltd. |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | T Cell Lymphoma; T-cell Leukemia |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | Targeted immunotherapies like chimeric antigen receptor |
MoA Biomarker | CD19-targeting CAR-T cells were successfully constructed, and the positive |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, followed by an intestinal perforation: a case report.. Mantle cell lymphoma is a diverse B-cell lymphoma with varying clinical behaviors. Treating relapsed or refractory mantle cell lymphoma is challenging, with Bruton's tyro… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 80.3% |
Clinical ORR | 80.3% |
Clinical PFS | 9.03 |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03483103 |
Clinical Data Tier / Score | A · 64 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | chimeric antigen receptor T cell treatment (chimeric antigen receptor T cell treatment) Yake Biotechnology Ltd.·FRα ORR 80.3% |
|---|---|
Overview Program | chimeric antigen receptor T cell treatment |
Overview Company | Yake Biotechnology Ltd. |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | T Cell Lymphoma; T-cell Leukemia |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | Targeted immunotherapies like chimeric antigen receptor |
MoA Biomarker | CD19-targeting CAR-T cells were successfully constructed, and the positive |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, followed by an intestinal perforation: a case report.. Mantle cell lymphoma is a diverse B-cell lymphoma with varying clinical behaviors. Treating relapsed or refractory mantle cell lymphoma is challenging, with Bruton's tyro… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 80.3% |
Clinical ORR | 80.3% |
Clinical PFS | 9.03 |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03483103 |
Clinical Data Tier / Score | A · 64 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교